Similar articles

• The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.

  Darken P, DePetrillo P, Reisner C, St Rose E, Dorinsky P. Darken P, et al. Pulm Pharmacol Ther. 2018 Jun;50:11-18. doi: 10.1016/j.pupt.2018.03.001. Epub 2018 Mar 13. Pulm Pharmacol Ther. 2018. PMID: 29544728 Clinical Trial.
• Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.

  Dunn LJ, Kerwin EM, DeAngelis K, Darken P, Gillen M, Dorinsky P. Dunn LJ, et al. Pulm Pharmacol Ther. 2020 Feb;60:101873. doi: 10.1016/j.pupt.2019.101873. Epub 2019 Dec 10. Pulm Pharmacol Ther. 2020. PMID: 31841699 Clinical Trial.
• Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.

  Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, Shimotai Y, Momma H, Ichinose M, Kawase T. Yamaya M, et al. Respir Investig. 2020 May;58(3):155-168. doi: 10.1016/j.resinv.2019.12.005. Epub 2020 Feb 21. Respir Investig. 2020. PMID: 32094077 Free PMC article.
• Glycopyrronium/Formoterol: A Review in COPD.

  Al-Salama ZT, Frampton JE. Al-Salama ZT, et al. Drugs. 2019 Sep;79(13):1455-1466. doi: 10.1007/s40265-019-01186-x. Drugs. 2019. PMID: 31468315 Review.
• Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.

  Scott LJ. Scott LJ. Drugs. 2012 Feb 12;72(3):395-414. doi: 10.2165/11208460-000000000-00000. Drugs. 2012. PMID: 22316354 Review.